Valuation: Mymetics Corporation

Market Cap 4L 4L 4L 3L 6L 4.19Cr 6L 41.85L 16.42L 2.09Cr 16.48L 16.12L 6.99Cr P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 7.21Cr 6.27Cr 5.84Cr 5.36Cr 10Cr 688.49Cr 10Cr 69Cr 27Cr 342.76Cr 27Cr 26Cr 1.15TCr EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+10,66,566.67%
Current month+10,66,566.67%
1 month+10,66,566.67%
3 months+10,66,566.67%
6 months+10,66,566.67%
Current year+10,66,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
29.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 19/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+10,66,566.67%+10,66,566.67%-88.10% 45
+2.35%+2.74%+38.10%+71.29% 5.65TCr
-0.21%-7.38%+27.52%+61.15% 5.36TCr
-2.44%+1.40%-15.61%-15.45% 2.29TCr
-2.85%-7.78%-9.28%+345.55% 2.14TCr
+2.49%-0.92%+23.57%-13.14% 2.03TCr
+0.79%-1.06%+33.99%-31.95% 1.76TCr
+0.58%-5.88%+19.40%+527.50% 1.47TCr
+3.41%-6.61%+162.81%+278.22% 1.35TCr
-5.25%-4.23%+42.32%+170.15% 1.33TCr
Average +4.43%-3.41%+1,06,688.95%+130.52% 2.34TCr
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2021 2022
Net sales 4L 4L 3L 3L 6L 4.1Cr 6L 41.01L 16.1L 2.04Cr 16.15L 15.79L 6.85Cr 10.28L 9L 8L 8L 14.42L 9.81Cr 14.64L 98.05L 38.48L 4.89Cr 38.61L 37.76L 16Cr
Net income -47.3L -41.12L -38.27L -35.14L -66.36L -45Cr -67.38L -4.51Cr -1.77Cr -22Cr -1.78Cr -1.74Cr -75Cr -48.05L -41.77L -38.88L -35.7L -67.41L -46Cr -68.45L -4.58Cr -1.8Cr -23Cr -1.8Cr -1.76Cr -77Cr
Net Debt 6.71Cr 5.83Cr 5.43Cr 4.98Cr 9.41Cr 640.54Cr 9.56Cr 64Cr 25Cr 318.89Cr 25Cr 25Cr 1.07TCr 7.17Cr 6.23Cr 5.8Cr 5.33Cr 10Cr 684.3Cr 10Cr 68Cr 27Cr 340.67Cr 27Cr 26Cr 1.14TCr
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
2
  1. Stock Market
  2. Stocks
  3. MYMX Stock